The pharmaceutical company Reig Jofre completed the acquisition of 100% of the diagnostics division of the biopharmaceutical company Oryzon Genomics.
With the purchase of Oryzon Genomics Diagnóstico S.L., Reig Jofre gets Control of 100% of GynEC®-DX, a molecular diagnostic test for early detection of endometrial cancer.
